A roundtable discussion on screening, managing and educating patients on Fuchs’ dystrophy in community optometry ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

The global Fuchs Endothelial Corneal Dystrophy (FECD) market is experiencing robust growth, driven by advancements in corneal transplantation techniques, increased awareness of rare ocular diseases, ...

NEW ORLEANS — Rho kinase inhibitor eyedrops stimulate the growth of corneal epithelium, according to a preliminary study in patients with Fuchs dystrophy. "Think outside the box," said Shigeru ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Researchers at Harvard Medical School have demonstrated the potent therapeutic effects of administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) through melanocortin receptor ...

The National Institutes of Health has renewed its funding of eye disease research led by Mark D. Parker, PhD, associate professor of physiology and biophysics. The National Eye Institute is funding a ...

Her five-year, $1.8 million R01 grant titled “Corneal Endothelium – Extracellular Matrix Interactions” is from the National Eye Institute. The cornea is a clear dome on the front of the eye that helps ...